妊娠期肝内胆汁淤积症不良围产结局与生化标志物的关联:聚合数据与个体患者数据Meta分析
该研究通过系统综述与聚合数据及个体患者数据Meta分析,评估妊娠期肝内胆汁淤积症(ICP)与不良围产结局的关联。
要点
- 胆汁酸<40 μmol/L的ICP孕妇死胎风险与一般人群相似,可 reassurance。
核心结论
- ICP单胎妊娠孕妇血清总胆汁酸≥100 μmol/L时死胎风险显著增加。
- 多数ICP孕妇胆汁酸低于此阈值,死胎风险与一般人群相似,但需重复检测直至分娩。
研究设计与样本
- 系统综述与聚合数据及个体患者数据Meta分析,检索PubMed、Web of Science、Embase至2018年6月1日。
- 纳入标准:基于瘙痒和血清胆汁酸升高诊断ICP,伴或不伴肝酶升高;病例对照、队列、人群研究或RCT,至少30例参与者。
- 排除高报告偏倚风险研究,包括病例报告、非队列研究、连续病例、会议摘要及无同行评议的读者来信。
- 随机效应Meta分析评估不良围产结局风险;个体数据采用logistic和逐步logistic回归分析生化标志物与不良结局关联。
关键数值与推荐
- ICP诊断基于瘙痒和血清胆汁酸升高,伴或不伴肝酶升高。
临床怎么用
- 对ICP单胎妊娠孕妇应监测血清总胆汁酸浓度,尤其关注≥100 μmol/L者。
- 胆汁酸<40 μmol/L者可 reassurance,但需重复检测直至分娩。
- 最大总胆汁酸浓度可用于评估死胎风险,ALT不推荐作为预测指标。
局限性
- 部分研究可能存在报告偏倚,已排除高偏倚风险研究。
- 个体患者数据来自部分研究,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcomes, but the association with the concentration of specific biochemical markers is unclear. We aimed to quantify the adverse perinatal effects of intrahepatic cholestasis of pregnancy in women with increased serum bile acid concentrations and determine whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth. METHODS: We did a systematic review by searching PubMed, Web of Science, and Embase databases for studies published from database inception to June 1, 2018, reporting perinatal outcomes for women with intrahepatic cholestasis of pregnancy when serum bile acid concentrations were available. Inclusion criteria were studies defining intrahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, with or without raised liver aminotransferase concentrations. Eligible studies were case-control, cohort, and population-based studies, and randomised controlled trials, with at least 30 participants, and that reported bile acid concentrations and perinatal outcomes. Studies at potential higher risk of reporter bias were excluded, including case reports, studies not comprising cohorts, or successive cases seen in a unit; we also excluded studies with high risk of bias from groups selected (eg, a subgroup of babies with poor outcomes were explicitly excluded), conference abstracts, and Letters to the Editor without clear peer review. We also included unpublished data from two UK hospitals. We did a random effects meta-analysis to determine risk of adverse perinatal outcomes. Aggregate data for maternal and perinatal outcomes were extracted from case-control studies, and individual patient data (IPD) were requested from study authors for all types of study (as no control group was required for the IPD analysis) to assess associations between biochemical markers and adverse outcomes using logistic and stepwise logistic regression. This study is registered with PROSPERO, number CRD42017069134. FINDINGS: We assessed 109 full-text articles, of which 23 studies were eligible for the aggregate data meta-analysis (5557 intrahepatic cholestasis of pregnancy cases and 165 136 controls), and 27 provided IPD (5269 intrahepatic cholestasis of pregnancy cases). Stillbirth occurred in 45 (0·83%) of 4936 intrahepatic cholestasis of pregnancy cases and 519 (0·32%) of 163 947 control pregnancies (odds ratio [OR] 1·46 [95% CI 0·73-2·89]; I2=59·8%). In singleton pregnancies, stillbirth was associated with maximum total bile acid concentration (area under the receiver operating characteristic curve [ROC AUC]) 0·83 [95% CI 0·74-0·92]), but not alanine aminotransferase (ROC AUC 0·46 [0·35-0·57]). For singleton pregnancies, the prevalence of stillbirth was three (0·13%; 95% CI 0·02-0·38) of 2310 intrahepatic cholestasis of pregnancy cases in women with serum total bile acids of less than 40 μmol/L versus four (0·28%; 0·08-0·72) of 1412 cases with total bile acids of 40-99 μmol/L (hazard ratio [HR] 2·35 [95% CI 0·52-10·50]; p=0·26), and versus 18 (3·44%; 2·05-5·37) of 524 cases for bile acids of 100 μmol/L or more (HR 30·50 [8·83-105·30]; p<0·0001). INTERPRETATION: The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton pregnancies when serum bile acids concentrations are of 100 μmol/L or more. Because most women with intrahepatic cholestasis of pregnancy have bile acids below this concentration, they can probably be reassured that the risk of stillbirth is similar to that of pregnant women in the general population, provided repeat bile acid testing is done until delivery. FUNDING: Tommy's, ICP Support, UK National Institute of Health Research, Wellcome Trust, and Genesis Research Trust.
引用
- Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019. PMID: 30773280. doi:10.1016/S0140-6736(18)31877-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。